Urban-Rural County and State Differences in Chronic Obstructive Pulmonary Disease — United States, 2015
Weekly / February 23, 2018 / 67(7);205–211
Janet B. Croft, PhD1; Anne G. Wheaton, PhD1; Yong Liu, MD1; Fang Xu, PhD1; Hua Lu, MS1; Kevin A. Matthews, MS1; Timothy J. Cunningham, ScD1; Yan Wang, PhD1; James B. Holt, PhD1 (View author affiliations)View suggested citation
What is already known about this topic?
Chronic obstructive pulmonary disease (COPD) is a leading cause of death and has been diagnosed in 15.5 million adults in 2015 in the United States. Risk factors include tobacco exposure, occupational and environmental exposures, respiratory infections, and genetics.
What is added by this report?
In 2015, rural U.S. residents had higher age-adjusted prevalence of COPD, of Medicare hospitalizations, and deaths caused by COPD than did residents living in micropolitan or metropolitan areas. Several states with the highest percentages of rural populations also had the highest estimates for all three measures.
What are the implications for public health practice?
Additional efforts are needed to prevent risk factors and overcome barriers to early diagnosis, and the appropriate treatment and management of COPD. Improving access to such health care might improve quality of life and reduce hospital readmissions among COPD patients and reduce COPD mortality.
Chronic obstructive pulmonary disease (COPD) accounts for the majority of deaths from chronic lower respiratory diseases, the third leading cause of death in the United States in 2015 and the fourth leading cause in 2016.* Major risk factors include tobacco exposure, occupational and environmental exposures, respiratory infections, and genetics.† State variations in COPD outcomes (1) suggest that it might be more common in states with large rural areas. To assess urban-rural variations in COPD prevalence, hospitalizations, and mortality; obtain county-level estimates; and update state-level variations in COPD measures, CDC analyzed 2015 data from the Behavioral Risk Factor Surveillance System (BRFSS), Medicare hospital records, and death certificate data from the National Vital Statistics System (NVSS). Overall, 15.5 million adults aged ≥18 years (5.9% age-adjusted prevalence) reported ever receiving a diagnosis of COPD; there were approximately 335,000 Medicare hospitalizations (11.5 per 1,000 Medicare enrollees aged ≥65 years) and 150,350 deaths in which COPD was listed as the underlying cause for persons of all ages (40.3 per 100,000 population). COPD prevalence, Medicare hospitalizations, and deaths were significantly higher among persons living in rural areas than among those living in micropolitan or metropolitan areas. Among seven states in the highest quartile for all three measures, Arkansas, Kentucky, Mississippi, and West Virginia were also in the upper quartile (≥18%) for rural residents. Overcoming barriers to prevention, early diagnosis, treatment, and management of COPD with primary care provider education, Internet access, physical activity and self-management programs, and improved access to pulmonary rehabilitation and oxygen therapy are needed to improve quality of life and reduce COPD mortality.
The National Center for Health Statistics (NCHS) 2013 Urban-Rural Classification Scheme for Counties, which uses 2010 U.S. Census population data and the February 2013 Office of Management and Budget designations of metropolitan statistical area, micropolitan statistical area, or noncore area (2), was used to classify urban-rural status of BRFSS respondents, Medicare inpatient claims, decedents, and populations at risk based on reported county of residence. The six categories include large central metropolitan, large fringe metropolitan, medium metropolitan, small metropolitan, micropolitan, and noncore (rural). Definitions and use of these categories have been described previously (2,3).
Prevalence of diagnosed COPD was estimated using the 2015 BRFSS survey, an annual state-based, random-digit–dialed cellular and landline telephone survey of the noninstitutionalized U.S. population aged ≥18 years§ that is conducted by state health departments in collaboration with CDC. In 2015, the median survey response rate for the 50 states and District of Columbia (DC) was 46.6% and ranged from 33.9% to 61.1%.¶ Diagnosed COPD was defined as an affirmative response to the question “Has a doctor, nurse, or other health professional ever told you that you had chronic obstructive pulmonary disease or COPD, emphysema, or chronic bronchitis?” State analyses included 426,838 (98.3%) respondents in the 50 states and DC after exclusions for missing information on COPD or age (Table 1). Urban-rural analyses included 426,736 (98.2%) respondents after excluding those who had missing information for COPD, age, or county code.
A multilevel regression and poststratification approach (4) was used to estimate model-predicted COPD prevalence for U.S. counties in 2015. High internal validity was determined by comparing modeled estimates with actual unweighted BRFSS survey estimates in 1,507 counties with ≥50 respondents (Pearson correlation coefficient = 0.68; p<0.001), and with weighted BRFSS survey estimates in 195 counties with ≥500 respondents and relative standard errors <0.30 (Pearson correlation coefficient = 0.74; p<0.001).
Medicare enrollment records and data from 100% of Part A (inpatient hospital) claims in 2015 were obtained from the Centers for Medicare & Medicaid Services. Analyses were limited to 30,212,024 living Medicare Part A enrollees aged ≥65 years who were eligible for fee-for-service hospitalizations on July 1, 2015, and all 335,362 fee-for-service inpatient hospital claims with a first-listed diagnosis of COPD that were submitted in 2015 for Medicare Part A enrollees aged ≥65 years. COPD was defined by International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) codes 490–492 or 496 or ICD-10-CM codes J40–J44.** Urban-rural analyses were limited to 335,102 (99.9%) hospital claims.
Mortality data for all ages were analyzed using CDC WONDER, an interactive public-use Web-based tool.†† CDC WONDER mortality data from NVSS contain information from all resident death certificates filed in the 50 states and DC. CDC WONDER queries generated numbers of deaths, age-adjusted death rates, 95% confidence intervals (CIs), and population denominators for groups defined by state and the 2013 NCHS urban-rural classification of decedents. Deaths caused by COPD were defined by ICD-10 codes J40–J44, in which COPD was the underlying cause of death on the death certificate. CDC also obtained population estimates for 2015 from CDC WONDER to calculate the percentage of U.S. and state residents who lived in a rural county as classified by the NCHS 2013 urban-rural county classification.
Age-adjusted prevalence of diagnosed COPD for persons aged ≥18 years, Medicare hospitalization rate for persons aged ≥65 years, death rate for all ages, and 95% CI for each estimate were calculated by urban-rural classification and state. For BRFSS analyses, statistical software was used to account for the complex sampling design. Differences in COPD prevalence among rural respondents compared with those of other urban-rural subgroups were determined by t-tests. Urban-rural differences in Medicare hospitalizations and death rates were determined by the Z-test. All two-sided tests were considered statistically significant at α = 0.05.
In 2015, approximately 15.5 million adults aged ≥18 years (unadjusted prevalence = 6.3% and age-adjusted prevalence = 5.9%) had self-reported diagnosed COPD. County-level estimates of COPD prevalence ranged from 3.2% to 15.6% (Figure). U.S. counties within the highest quartile of county-level estimates (8.5%−15.6%) tended to be located in nonmetropolitan areas of Alabama, Arizona, Arkansas, Georgia, Kentucky, Maine, Michigan, Missouri, Ohio, Oklahoma, Tennessee, and West Virginia (Figure).
Age-adjusted prevalence of diagnosed COPD among adults aged ≥18 years increased with less urbanicity from 4.7% among populations living in large metropolitan centers to 8.2% among adults living in rural areas (Table 1). Medicare hospitalizations (per 1,000 enrollees) for COPD were 11.4 among enrollees aged ≥65 years living in large metropolitan centers and 13.8 among those living in rural areas. Age-adjusted death rates (per 100,000 population) for COPD as the underlying cause also increased with less urbanicity from 32.0 for U.S. residents living in large metropolitan centers to 54.5 for those living in rural areas. There was a consistent pattern for significantly higher estimates of COPD measures from all three independent data systems among adults living in rural areas than among those living in micropolitan or metropolitan areas.
Overall 5.9% of U.S. residents lived in rural counties in 2015. State-specific percentages of rural residents ranged from zero percent in Connecticut, Delaware, District of Columbia, New Jersey, and Rhode Island to 34.7% in Montana (Table 2). State-specific age-adjusted prevalence of COPD among adults aged ≥18 years in 2015 ranged from 3.8% in Utah to 12.0% in West Virginia. State-specific age-adjusted Medicare hospitalization rates (per 1,000 enrollees) among enrollees aged ≥65 years ranged from 3.7 in Utah to 19.7 in West Virginia. State-specific age-adjusted death rates (per 100,000 population) in 2015 ranged from 15.8 in Hawaii to 64.3 in Oklahoma. Of the seven states (Alabama, Arkansas, Indiana, Kentucky, Mississippi, Tennessee, and West Virginia) that were in the highest quartiles for all three measures in 2015, four states (Arkansas, Kentucky, Mississippi, and West Virginia) were also in the highest quartile (≥18%) for percentage of rural residents.
In 2015, rural U.S. residents experienced higher age-adjusted COPD prevalence, Medicare hospitalizations for COPD as the first-listed diagnosis, and deaths caused by COPD than did residents in micropolitan or metropolitan areas. In addition to the major risk factors for COPD, which include tobacco smoke, environmental and occupational exposures, respiratory infections, and genetics, correlates include older ages, low socioeconomic status, and asthma history (5,6). Rural populations might have higher COPD risk because these populations have a greater proportion with a history of smoking (3), more secondhand smoke exposure but less access to smoking cessation programs,§§ and higher proportions of uninsured or lower socioeconomic residents, which might have limited access to early diagnosis, treatment, and management of COPD.¶¶ Rural respiratory exposures might include mold spores, organic toxic dust, and nitrogen dioxide, which are associated with COPD risk (7).
COPD management includes efforts to slow declining lung function, improve exercise tolerance, and prevent and treat exacerbations. Treatments include pulmonary rehabilitation, oxygen therapy, and medications. Smoking cessation programs, routine influenza and pneumococcal vaccinations, regular physical activity, and reductions in occupational and environmental exposures are also important. Barriers to health care in rural areas include cultural perceptions about seeking care, travel distance, absence of services, and financial burden (8). Access to early diagnosis, prompt treatment, and management of COPD by a pulmonologist is difficult for rural adults with COPD because of limited geographic accessibility to this COPD specialty (9). Therefore, much of the COPD in rural areas is diagnosed and managed by primary care providers (9). Level of care and patient-physician communication might vary, given that 27% of adults with COPD symptoms in 2016 reported that they had not talked with their physician about these symptoms (10). In a primary care physician survey, 71% said that they would use spirometry to assess patients with COPD symptoms, but they also reported that important barriers to diagnosing COPD included patient failure to report COPD symptoms or smoking history, poor treatment adherence, more immediate competing health issues, and diagnostic procedure costs (10). Whereas 68% of primary care physicians were aware that pulmonary rehabilitation programs were available to their patients, only 38% routinely prescribed this therapy for COPD patients (10). However, rural areas might have limited availability to these programs. Provision of online health care services (i.e., telemedicine) in rural areas could reduce some of these barriers by providing health education and support websites to patients and caregivers, appointment assistance, and ability to check assessment results online; however, lack of Internet access is still a barrier in some rural populations (8).
The findings in this report are subject to at least eight limitations. First, self-reported diagnosed COPD in BRFSS cannot be validated with medical records and might be subject to recall and social desirability biases; however, urban-rural variations in prevalence were similar to Medicare claims. Second, the BRFSS study population does not include adults who live in long-term care facilities, prisons, and other facilities; thus, findings are not generalizable to those populations. Third, state BRFSS response rates were relatively low, and response rates cannot be obtained by urban-rural classification. This might have resulted in overestimates or underestimates of COPD prevalence; however, a strength is that BRFSS provides large, stable sample sizes for all six urban-rural classifications. Fourth, the assumption that the six urban-rural classifications reflect consistent types of distinct populations and social environments within and across each state could potentially be incorrect. Fifth, county-level estimates are modeled and based on population characteristics such as distributions of older adults in the county; furthermore, it is not known how previous or current local interventions (e.g., tobacco cessation policies and programs) might have affected current COPD prevalence. Sixth, Medicare claims should not be interpreted as unique prevalent cases because some might reflect readmissions; however, these COPD estimates do reflect the actual Medicare burden for hospital facilities, pulmonary rehabilitation services, health care providers, caregivers, and other resources. Seventh, both Medicare hospital claims and death certificates might be subject to reporting preferences for certain diseases as the first-listed or underlying cause if there is a consistent regional or urban-rural preference. Finally, although the data reported here show higher COPD hospitalization and death rates for rural populations, they do not assess whether hospitalization and death rates among patients with COPD vary by urbanicity.
Higher burdens of COPD among rural U.S. residents highlight needs for continued tobacco cessation programs and policies to prevent COPD and improve pulmonary function among smokers. Known barriers to care in rural areas suggest a need for improved access for adults with COPD to treatment strategies (pulmonary rehabilitation and oxygen therapy) and comprehensive chronic disease self-management programs. Health care providers and community partners who serve rural residents can help adults with COPD increase access to and participation in health care interventions. Federal agencies are promoting collaborative and coordinated efforts to educate the public, providers, patients, and caregivers about COPD and improve the prevention, diagnosis, and treatment of COPD. The COPD National Action Plan*** includes goals to expand access to online communities, develop clinical decision tools for primary health care providers, and conduct research to improve access to care for COPD in hard-to-reach areas. Promoting these efforts has the potential to improve quality of life for COPD patients and reduce hospital readmissions and COPD mortality.
Conflict of Interest
No conflicts of interest were reported.
Corresponding author: Janet B. Croft, email@example.com, 770-488-2566.
* Leading causes of death reported for 2015 at https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_05.pdfpdf icon and for 2016 at https://www.cdc.gov/nchs/products/databriefs/db293.htm.
¶ Response rates for BRFSS are calculated using standards set by American Association for Public Opinion Research response rate formula 4. The response rate is the number of respondents who completed the survey as a proportion of all eligible and likely eligible persons. http://www.aapor.org/AAPOR_Main/media/publications/Standard-Definitions20169theditionfinal.pdfpdf iconexternal icon. Response rates in 2015 for individual states are available at https://www.cdc.gov/brfss/annual_data/2015/pdf/2015-sdqr.pdfpdf icon.
** International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) codes for COPD include 490 (bronchitis, not specified as acute or chronic), 491 (chronic bronchitis), 492 (emphysema), or 496 (chronic airway obstruction); ICD-10-CM codes include J40 (bronchitis, not specified as acute or chronic), J41 (simple and mucopurulent chronic bronchitis), J42 (unspecified chronic bronchitis), J43 (emphysema), or J44 (other COPD).
†† https://wonder.cdc.gov. Population estimates for groups defined by urban-rural status and state are bridged-race estimates of the July 1, 2015, resident population from the Vintage 2015 postcensal series that were released on June 28, 2016.
- Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH. COPD surveillance—United States, 1999–2011. Chest 2013;144:284–305. CrossRefexternal icon PubMedexternal icon
- Ingram DD, Franco SJ. 2013 NCHS urban-rural classification scheme for counties. Vital Health Stat 2 2014;166:1–73. PubMedexternal icon
- Matthews KA, Croft JB, Liu Y, et al. Health-related behaviors by urban-rural county classification—United States, 2013. MMWR Surveill Summ 2017;66(No. SS-5). CrossRefexternal icon PubMedexternal icon
- Zhang X, Holt JB, Lu H, et al. Multilevel regression and poststratification for small-area estimation of population health outcomes: a case study of chronic obstructive pulmonary disease prevalence using the behavioral risk factor surveillance system. Am J Epidemiol 2014;179:1025–33. CrossRefexternal icon PubMedexternal icon
- Wheaton AG, Cunningham TJ, Ford ES, Croft JB. Employment and activity limitations among adults with chronic obstructive pulmonary disease—United States, 2013. MMWR Morb Mortal Wkly Rep 2015;64:289–95. PubMedexternal icon
- CDC. Chronic obstructive pulmonary disease among adults—United States, 2011. MMWR Morb Mortal Wkly Rep 2012;61:938–43. PubMedexternal icon
- Deligiannidis KE. Primary care issues in rural populations. Prim Care 2017;44:11–9. CrossRefexternal icon PubMedexternal icon
- Douthit N, Kiv S, Dwolatzky T, Biswas S. Exposing some important barriers to health care access in the rural USA. Public Health 2015;129:611–20. CrossRefexternal icon PubMedexternal icon
- Croft JB, Lu H, Zhang X, Holt JB. Geographic accessibility of pulmonologists for adults with COPD: United States, 2013. Chest 2016;150:544–53. CrossRefexternal icon PubMedexternal icon
- National Heart, Lung, and Blood Institute. COPD: tracking perceptions of individuals affected, their caregivers, and the physicians who diagnose and treat them. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2017. https://www.nhlbi.nih.gov/health/educational/copd/health-care-professionals/COPD-Tracking-Perceptions-of-Individuals-Affected-Their-Caregivers-and-the-Physicians-Who-Diagnose-and-Treat-Them.pdfpdf iconexternal icon
FIGURE. Unadjusted prevalence of diagnosed chronic obstructive pulmonary disease among adults aged ≥18 years, by county — United States, 2015
The figure above is a U.S. map showing the unadjusted prevalence of diagnosed chronic obstructive pulmonary disease among adults aged ≥18 years, by county, in 2015.
|COPD measure||Overall†||Large metropolitan center||Large fringe metropolitan||Medium metropolitan||Small metropolitan||Micropolitan||Noncore (rural)|
|Estimated no. in population (rounded to 1,000s) with diagnosed COPD||15,460,000||3,566,000||3,406,000||3,452,000||1,661,000||1,796,000||1,576,000|
|% (95% CI)||5.9 (5.8−6.0)||4.7 (4.5−5.0)||5.3 (5.0−5.5)||6.4 (6.2−6.7)||7.0 (6.6−7.3)||7.6 (7.2−8.0)||8.2 (7.8−8.7)|
|Number of Medicare enrollees, aged ≥65 years, in fee-for-service plan||30,212,024||6,812,852||7,402,029||6,510,167||3,361,075||3,400,705||2,701,592|
|Hospital claims with COPD as first-listed diagnosis||335,362||74,616||78,220||68,291||35,798||41,653||36,524|
|Rate per 1,000 (95% CI)||11.5 (11.4−11.5)||11.4 (11.3−11.5)||11.0 (11.0−11.1)||10.8 (10.7−10.9)||10.9 (10.8−11.0)||12.5 (12.4−12.6)||13.8 (13.6−13.9)|
|U.S. population (all ages)||321,418,820||98,997,449||79,867,097||67,041,154||29,346,517||27,260,617||18,905,986|
|Number of deaths with COPD as underlying cause||150,350||32,309||32,718||33,619||17,419||19,019||15,266|
|Rate per 100,000 (95% CI)||40.3 (40.1−40.5)||32.0 (31.6−32.3)||36.2 (35.8−36.6)||41.9 (41.5−42.4)||47.0 (46.3−47.7)||52.8 (52.1−53.6)||54.5 (53.6−55.4)|
|State||% rural residents*||Rank order in % rural residents||No. in U.S. population with COPD†||% (95% CI)§||No. of Medicare hospitalizations¶||Rate per 1,000 (95% CI)¶||No. of deaths||Rate per 100,000 (95% CI)**|
|Alabama||12.8||16||393,000||9.9 (9.0−10.9)||7,691||14.3 (14.0−14.6)||3,217||55.2 (53.3−57.1)|
|Alaska||26.1||5||22,000||4.1 (3.3−5.1)||380||6.3 (5.6−6.9)||193||36.1 (30.7−41.6)|
|Arizona||1.5||38||325,000||5.8 (5.2−6.5)||4,711||8.3 (8.1−8.5)||3,570||42.4 (41.0−43.8)|
|Arkansas||19.1||11||219,000||9.1 (8.0−10.5)||4,806||13.3 (12.9−13.7)||2,234||61.3 (58.7−63.8)|
|California||0.7||41||1,207,000||4.0 (3.6−4.4)||20,289||7.9 (7.8−8.1)||13,092||31.8 (31.3−32.4)|
|Colorado||5.6||26||179,000||4.2 (3.8−4.6)||2,376||6.4 (6.1−6.6)||2,514||46.6 (44.8−48.5)|
|Connecticut||0.0||43||143,000||4.6 (4.1−5.1)||3,798||9.7 (9.4−10.0)||1,309||28.4 (26.8−30.0)|
|Delaware||0.0||43||51,000||6.3 (5.3−7.5)||1,137||8.6 (8.1−9.1)||494||40.9 (37.3−44.6)|
|DC||0.0||43||28,000||5.9 (4.9−7.2)||445||7.5 (6.8−8.2)||134||21.5 (17.8−25.2)|
|Florida||1.7||37||1,117,000||6.0 (5.4−6.6)||32,274||15.9 (15.7−16.1)||11,461||37.4 (36.7−38.1)|
|Georgia||7.7||22||532,000||6.7 (6.0−7.6)||9.425||11.9 (11.7−12.2)||4,501||45.7 (44.3−47.1)|
|Hawaii||0.0||43||48,000||4.1 (3.5−4.9)||663||6.2 (5.7−6.7)||303||15.8 (14.0−17.6)|
|Idaho||8.3||21||59,000||4.5 (3.9−5.3)||942||6.3 (5.9−6.7)||817||44.8 (41.7−47.9)|
|Illinois||4.7||29||568,000||5.4 (4.7−6.3)||14,964||11.4 (11.2−11.6)||5,360||36.8 (35.8−37.8)|
|Indiana||7.0||23||400,000||7.4 (6.6−8.3)||9,048||13.1 (12.9−13.4)||4,096||53.7 (52.1−55.4)|
|Iowa||25.2||7||136,000||5.2 (4.6−6.0)||3,407||8.3 (8.0−8.6)||1,949||47.5 (45.4−49.7)|
|Kansas||13.5||15||134,000||5.8 (5.5−6.2)||2,764||8.0 (7.7−8.3)||1,665||48.5 (46.1−50.8)|
|Kentucky||22.3||8||410,000||11.2 (10.2−12.3)||8,618||19.1 (18.7−19.5)||3,280||63.2 (61.1−65.4)|
|Louisiana||7.7||22||265,000||7.1 (6.3−8.0)||5,452||13.5 (13.2−13.9)||2,125||42.1 (40.3−43.9)|
|Maine||31.8||2||86,000||7.0 (6.3−7.8)||1,986||11.3 (10.8−11.8)||1,003||52.5 (49.2−55.8)|
|Maryland||1.4||39||282,000||5.8 (5.1−6.5)||5,841||8.4 (8.2−8.6)||1,945||29.2 (27.9−30.5)|
|Massachusetts||0.2||42||303,000||5.3 (4.8−6.0)||8,566||11.4 (11.2−11.7)||2,668||31.6 (30.4−32.8)|
|Michigan||6.7||24||584,000||6.9 (6.3−7.6)||13,338||13.9 (13.7−14.1)||5,700||46.2 (45.0−47.4)|
|Minnesota||10.5||18||187,000||4.2 (3.8−4.5)||3,910||12.7 (12.3−13.1)||2,273||35.1 (33.7−36.6)|
|Mississippi||22.2||9||173,000||7.2 (6.4−8.2)||5,040||14.3 (13.9−14.7)||1,865||55.3 (52.8−57.8)|
|Missouri||13.7||14||387,000||7.9 (7.1−8.9)||7,587||12.2 (11.9−12.5)||3,843||51.4 (49.8−53.1)|
|Montana||34.7||1||45,000||5.0 (4.3−5.8)||918||7.0 (6.5−7.4)||663||48.8 (45.0−52.5)|
|Nebraska||18.0||12||77,000||5.0 (4.6−5.5)||2,061||8.9 (8.5−9.3)||1,127||50.0 (47.1−53.0)|
|Nevada||1.1||40||145,000||6.2 (5.1−7.6)||2,079||9.0 (8.6−9.4)||1,591||53.2 (50.5−55.8)|
|New Hampshire||3.6||32||70,000||6.1 (5.3−6.9)||1,794||9.5 (9.0−9.9)||681||40.3 (37.3−43.4)|
|New Jersey||0.0||43||341,000||4.6 (4.1−5.1)||10,454||10.1 (9.9−10.3)||3,057||28.2 (27.1−29.2)|
|New Mexico||4.4||30||94,000||5.5 (4.9−6.3)||1,530||8.1 (7.7−8.6)||1,079||43.4 (40.8−46.0)|
|New York||2.0||36||882,000||5.3 (4.8−5.8)||20,489||12.3 (12.2−12.5)||6,755||28.3 (27.6−29.0)|
|North Carolina||6.3||25||573,000||7.0 (6.3−7.7)||10,632||11.2 (11.0−11.4)||5,077||44.1 (42.9−45.3)|
|North Dakota||26.5||4||30,000||4.8 (4.2−5.6)||695||8.4 (7.8−9.0)||340||38.7 (34.5−42.9)|
|Ohio||3.9||31||705,000||7.1 (6.5−7.9)||16,189||16.7 (16.4−16.9)||7,000||48.0 (46.9−49.1)|
|Oklahoma||13.9||13||255,000||8.2 (7.4−9.1)||5,563||12.6 (12.3−12.9)||2,863||64.3 (61.9−66.7)|
|Oregon||2.4||34||174,000||5.1 (4.5−5.8)||2,442||7.6 (7.3−7.9)||2,037||40.7 (38.9−42.5)|
|Pennsylvania||3.2||33||701,000||6.2 (5.5−7.0)||17,795||14.9 (14.7−15.2)||6,457||36.7 (35.8−37.6)|
|Rhode Island||0.0||43||52,000||5.7 (4.9−6.5)||1,435||15.2 (14.4−16.0)||498||35.8 (32.6−39.0)|
|South Carolina||6.3||25||272,000||6.7 (6.1−7.3)||5,666||10.0 (9.7−10.2)||2,828||48.5 (46.6−50.3)|
|South Dakota||25.4||6||36,000||5.2 (4.4−6.1)||976||9.4 (8.8−10.0)||488||44.0 (40.0−47.9)|
|Tennessee||9.8||19||486,000||8.9 (8.0−10.0)||9,875||15.7 (15.3−16.0)||4,151||53.7 (52.1−55.4)|
|Texas||5.1||27||1,032,000||5.1 (4.6−5.7)||22,975||11.7 (11.5−11.9)||9,939||40.2 (39.4−41.0)|
|Utah||4.8||28||75,000||3.8 (3.4−4.3)||683||3.7 (3.4−4.0)||770||32.3 (30.0−34.6)|
|Vermont||26.1||5||31,000||5.6 (4.9−6.3)||660||6.9 (6.4−7.5)||345||41.0 (36.6−45.4)|
|Virginia||9.3||20||374,000||5.5 (5.0−6.0)||7,248||8.1 (7.9−8.2)||3,258||35.8 (34.6−37.1)|
|Washington||2.2||35||335,000||5.8 (5.3−6.3)||3,608||5.4 (5.3−5.6)||3,016||37.9 (36.5−39.3)|
|West Virginia||21.9||10||194,000||12.0 (11.1−13.0)||4,388||19.7 (19.1−20.2)||1,597||63.1 (60.0−66.3)|
|Wisconsin||12.5||17||209,000||4.2 (3.6−4.8)||5,179||10.3 (10.0−10.6)||2,761||38.1 (36.6−39.5)|
|Wyoming||27.4||3||32,000||6.8 (5.9−7.9)||570||7.7 (7.1−8.4)||361||55.9 (50.0−61.7)|
|50 states and DC||5.9||—||15,460,000||5.9 (5.8−6.0)||335,362||11.5 (11.4−11.5)||150,350||40.3 (40.1−40.5)|
Suggested citation for this article: Croft JB, Wheaton AG, Liu Y, et al. Urban-Rural County and State Differences in Chronic Obstructive Pulmonary Disease — United States, 2015. MMWR Morb Mortal Wkly Rep 2018;67:205–211. DOI: http://dx.doi.org/10.15585/mmwr.mm6707a1external icon.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.